President Trump speaks to business leaders in Abu Dhabi:

'We're making great progress towards a $1.4 TRILLION dollars that UAE has announced that it intends to spend in the United States.' 🔥

President Donald Trump concluded a multi-nation trip to the Middle East on Friday, announcing a slate of large-scale economic agreements with Saudi Arabia, Qatar, and the UAE. ⁠
⁠
In Saudi Arabia, he signed a $600 billion “strategic economic partnership” with Crown Prince Mohammed bin Salman that includes investments in U.S. energy infrastructure, artificial intelligence data centers, and a $142 billion defense package. ⁠
⁠
In Qatar, Trump finalized a $1.2 trillion deal featuring the purchase of 210 Boeing aircraft by Qatar Airways for $96 billion, plus investments in quantum technologies, energy, and workforce development. He also expanded a $1.4 trillion UAE agreement announced in March with an added $200 billion in commercial projects.⁠
⁠
Alongside the economic announcements, Trump delivered a message to Iran regarding its nuclear ambitions. ⁠
⁠
“If Iran’s leadership rejects the olive branch and continues to attack their neighbors, then we will have no choice but to inflict massive maximum pressure,” he said in Saudi Arabia. ⁠
⁠
Trump also lifted U.S. sanctions on Syria, citing the fall of the Assad regime and a shift in power to Hay’at Tahrir al-Sham. “I am also ordering the cessation of sanctions against Syria to give them a fresh start,” he said. The administration confirmed that Secretary of State Marco Rubio would meet with Syria’s foreign minister in Turkey.⁠
⁠
Slide 1 photo by Win McNamee/Getty Images

“We’re setting records on this trip. We're bringing a lot of investment back into the United States of America. We'll be well over $10 trillion. I want to thank your Highness for helping with that number... It's going to be a great investment for you.” –President Donald J. Trump 🇺🇸🇶🇦

President Trump announced plans to sign an executive order aimed at reducing U.S. drug prices by implementing a "Most Favored Nation" (MFN) policy. This policy would direct the Department of Health and Human Services to negotiate lower drug prices with pharmaceutical companies, tying U.S. prices to the lowest prices paid by other countries. ⁠
⁠
The order is set to focus on Medicare Part B drugs, which include medications administered in a doctor's office, such as cancer treatments. Trump claims the policy could reduce costs by 30% to 80% and save the U.S. "TRILLIONS OF DOLLARS."⁠
⁠
This latest order is a continuation of Trump's efforts from his first term to address the high cost of U.S. drugs via price controls. In 2020, he signed a similar executive order aimed at tying U.S. drug prices to international benchmarks, but the proposal faced significant opposition from the pharmaceutical industry. Critics argued that such a policy would harm innovation and reduce access to new medications. Trump's 2020 attempt was blocked by a federal court after he left office, preventing its implementation under President Biden. ⁠
⁠
The MFN policy is likely to face similar resistance from the pharmaceutical industry, which argues that forcing lower prices could stifle innovation, leading to fewer new medicines and potentially harming the U.S.'s role as a global leader in drug development. ⁠
⁠
Pharmaceutical companies contend that the policy would grant foreign governments excessive influence over U.S. drug pricing, undermining the ability of the U.S. market to set fair and competitive prices. Despite this opposition, the proposal reflects ongoing frustrations with U.S. drug pricing, a long-standing issue that has drawn bipartisan criticism.⁠
⁠
Head to the link in bio for the full story